Rank #1832BDTX

Black Diamond Therapeutics, Inc

$2.30

1.77% (Daily)

Market Cap

$131.04M

Revenue

$70.00M

Rank by MCap

#1832

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Mark A. Velleca M.D., Ph.D.

Headquarters

Cambridge, MA

Employees

About Black Diamond Therapeutics, Inc

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also dev...